# Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia

> **NCT00006363** · PHASE3 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 720 (actual)

## Conditions studied

- Adult Acute Basophilic Leukemia
- Adult Acute Eosinophilic Leukemia
- Adult Acute Erythroid Leukemia (M6)
- Adult Acute Megakaryoblastic Leukemia (M7)
- Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Adult Acute Monoblastic Leukemia (M5a)
- Adult Acute Monoblastic Leukemia and Acute Monocytic Leukemia (M5)
- Adult Acute Monocytic Leukemia (M5b)
- Adult Acute Myeloblastic Leukemia With Maturation (M2)
- Adult Acute Myeloblastic Leukemia Without Maturation (M1)
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Adult Acute Myeloid Leukemia With Del(5q)
- Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
- Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
- Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
- Adult Acute Myelomonocytic Leukemia (M4)
- Adult Erythroleukemia (M6a)
- Adult Pure Erythroid Leukemia (M6b)
- Childhood Acute Basophilic Leukemia
- Childhood Acute Eosinophilic Leukemia
- Childhood Acute Erythroleukemia (M6)
- Childhood Acute Megakaryocytic Leukemia (M7)
- Childhood Acute Minimally Differentiated Myeloid Leukemia (M0)
- Childhood Acute Monoblastic Leukemia (M5a)
- Childhood Acute Monoblastic Leukemia and Acute Monocytic Leukemia (M5)
- Childhood Acute Monocytic Leukemia (M5b)
- Childhood Acute Myeloblastic Leukemia With Maturation (M2)
- Childhood Acute Myeloblastic Leukemia Without Maturation (M1)
- Childhood Acute Myelomonocytic Leukemia (M4)
- Childhood Myelodysplastic Syndromes
- de Novo Myelodysplastic Syndromes
- Untreated Adult Acute Myeloid Leukemia
- Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies

## Interventions

- **DRUG:** cytarabine
- **DRUG:** daunorubicin hydrochloride
- **DRUG:** etoposide
- **DRUG:** valspodar
- **BIOLOGICAL:** filgrastim
- **DRUG:** busulfan
- **PROCEDURE:** autologous hematopoietic stem cell transplantation
- **PROCEDURE:** peripheral blood stem cell transplantation
- **BIOLOGICAL:** aldesleukin
- **OTHER:** clinical observation
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT00006363
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-11
- **Primary completion:** 2005-06
- **Final completion:** —
- **Target enrollment:** 720 (ACTUAL)
- **Last updated:** 2013-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00006363

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00006363, "Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT00006363. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*